Evidence map›Paper›PMID 37276782›Full record

ArticleSeminars in pediatric surgery2023

Stem cells as a therapeutic avenue for active and long-term complications of Necrotizing Enterocolitis.

Fikir M Mesfin, Krishna Manohar, W Christopher Shelley, John P Brokaw, Jianyun Liu, Minglin Ma, Troy A Markel

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Seminars in pediatric surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Necrotizing enterocolitis.Nature reviews. Disease primers · 2026
    Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Fikir M MesfinDepartment of Surgery, Section of Pediatric Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
Krishna ManoharDepartment of Surgery, Section of Pediatric Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
W Christopher ShelleyDepartment of Surgery, Section of Pediatric Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
John P BrokawDepartment of Surgery, Section of Pediatric Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
Jianyun LiuDepartment of Surgery, Section of Pediatric Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
Minglin MaDepartment of Biological and Environmental Engineering, Cornell University, Ithaca, NY, USA.
Troy A MarkelDepartment of Surgery, Section of Pediatric Surgery, Indiana University School of Medicine, Indianapolis, IN, USA; Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA. Electronic address: tmarkel@iupui.edu.
Indiana University – Purdue University Indianapolis · USIndiana University School of MedicineCornell University · US

Funding

Project-005U54DK106846 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Reuben Kapur, Karen Elizabeth Pollok · 2015 to 2026
$9.7M
Neonatal gut-on-a-chip platform for high content drug testing and precision medicineR01HD105301 · NICHD · WASHINGTON UNIVERSITY · PI GOOD, MISTY L, MAGNESS, SCOTT T · 2021 to 2024
$2.4M
NICHD NIH HHS R01 HD105301NIDDK NIH HHS U54 DK106846
6 · The paper itself

Abstract

Necrotizing enterocolitis (NEC) is a devastating neonatal intestinal disease associated with significant morbidity and mortality. Although decades of research have been dedicated to understanding the pathogenesis of NEC and developing therapies, it remains the leading cause of death among neonatal gastrointestinal diseases. Mesenchymal stem cells (MSCs) have garnered significant interest recently as potential therapeutic agents for the treatment of NEC. They have been shown to rescue intestinal injury and reduce the incidence and severity of NEC in various preclinical animal studies. MSCs and MSC-derived organoids and tissue engineered small intestine (TESI) have shown potential for the treatment of long-term sequela of NEC such as short bowel syndrome, neurodevelopmental delay, and chronic lung disease. Although the advances made in the use of MSCs are promising, further research is needed prior to the widespread use of these cells for the treatment of NEC.

Indexed as

Enterocolitis, NecrotizingInfant, Newborn, DiseasesShort Bowel SyndromeAnimalsHumansInfant, NewbornIntestinesStem CellsBronchopulmonary dysplasiaIntestinal failureMesenchymal stem cellsNeurodevelopmental delay

Identifiers

PMID37276782
PMCPMC10330659
OpenAlexW4378983346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.